SCHEMBL7710941

SCHEMBL7710941

CN1Oc2cc3c(cc2CC1=S)CCCCCC3

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7002280 0.80 GAA (0.34)
SCHEMBL7001476 0.80 GAA (0.34)
SCHEMBL1760720 0.61 TSHR (0.50)
SCHEMBL10969946 0.59 CDC25B (0.40)
SCHEMBL28303303 0.59 CDC25B (0.43)
SCHEMBL10487287 0.58 DRD2 (0.44)
SCHEMBL25202453 0.58 CDC25B (0.48)
SCHEMBL30635627 0.58 CDC25B (0.48)
SCHEMBL9782638 0.56 CDC25B (0.37)
SCHEMBL10163669 0.56 CHRNA7 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed